Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles

Novo Nordisk reported Q2 earnings of $0.97 per ADR, surpassing the $0.93 consensus, but revenues of $11.68 billion missed expectations. The company subsequently lowered its 2025 sales and operating profit guidance to 8-14% and 10-16% growth respectively, citing weaker-than-anticipated momentum for its GLP-1 drugs, particularly Wegovy in the U.S. due to illegal compounded versions and intensifying competition from Eli Lilly. NVO is addressing these challenges through legal action and pipeline expansion, including oral Wegovy and other GLP-1 indications, aiming to strengthen its market position.

Analysis

Novo Nordisk's second-quarter 2025 results present a challenging picture, as an earnings per share beat to $0.97 was overshadowed by a revenue miss at $11.68 billion and, more critically, a significant downward revision of its full-year 2025 guidance. The company now projects sales growth of 8-14% and operating profit growth of 10-16%, a sharp reduction from the prior 13-21% and 16-24% ranges, respectively. This downgrade is a direct consequence of decelerating momentum in its core Diabetes and Obesity Care segment. Specifically, while Wegovy sales grew an impressive 75% year-over-year, the growth rate is slowing due to persistent competition from illegal compounded GLP-1 alternatives in the U.S. and weaker-than-anticipated patient uptake. Compounding this issue is intensifying pressure from Eli Lilly, whose competing drugs have contributed to a 1.4% erosion of Novo Nordisk's global diabetes market share to 32.6% over the past year, a trend reflected in NVO's 45.1% year-to-date stock price decline. In response, the company is pursuing legal action and banking on future catalysts, including an FDA decision on a first-to-market oral version of Wegovy by year-end, label expansions for its key drugs, and a new exclusive formulary agreement with CVS, which could bolster sales in the second half of the year.

Key Decisions for Investors

• Investors must recalibrate valuation models to account for the significantly lower 2025 guidance, as the previous high-growth thesis for the GLP-1 franchise is now challenged.
• Closely monitor the effectiveness of Novo Nordisk's initiatives against compounded drugs and the initial sales impact from the exclusive CVS formulary coverage beginning in H2 2025.
• The primary competitive threat from Eli Lilly requires careful tracking of LLY's market share gains, while the FDA's year-end decision on oral Wegovy represents a critical potential catalyst for NVO.
• Given the stock's 45.1% year-to-date decline, an assessment is required to determine if the current valuation adequately prices in the reduced growth outlook and competitive risks.